Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMJS4RP)

Drug Name
PMID26882240-Compound-32 Drug Info
Cross-matching ID
PubChem CID
5288674
ChEBI ID
CHEMBL65324
CAS Number
CAS 467214-20-6
TTD Drug ID
D03OYJ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Protein processing in endoplasmic reticulum 2.72 0.00e+0 127/171 (74.27%) HSPA1A;HSPH1;HSPA8;...
Antigen processing and presentation 2.23 0.00e+0 60/78 (76.92%) HSPA1A;HSPA8;HSPA6;...
Longevity regulating pathway 2.00 9.22e-3 90/151 (59.6%) HSPA1A;HSPA8;HSPA6;...
Legionellosis 1.96 8.65e-3 51/57 (89.47%) HSPA1A;HSPA8;HSPA6;...
Spliceosome 1.80 2.63e-2 101/150 (67.33%) HSPA1A;HSPA8;HSPA6;...
Estrogen signaling pathway 1.70 4.94e-2 119/137 (86.86%) HSPA1A;HSPA8;HSPA6;...
Long-term potentiation -1.72 4.29e-2 61/67 (91.04%) MAPK1;HRAS;PRKCB;...
Epstein-Barr virus infection -1.73 4.56e-2 189/202 (93.56%) PSMD3;HLA-DQB1;CASP3;...
IL-17 signaling pathway -1.74 4.12e-2 84/94 (89.36%) CXCL6;MAPK7;TRAF4;...
TGF-beta signaling pathway -1.76 3.72e-2 81/94 (86.17%) BMPR1A;TFDP1;MAPK1;...
Phototransduction -1.76 4.18e-2 21/29 (72.41%) CALML3;CALML5
Leishmaniasis -1.78 3.68e-2 67/77 (87.01%) IRAK1;HLA-DPB1;MAPK1;...
Nucleotide excision repair -1.86 1.93e-2 40/47 (85.11%) ERCC2;RBX1;PCNA;...
Base excision repair -2.05 2.57e-3 29/33 (87.88%) MUTYH;POLE3;POLD2;...
Homologous recombination -2.07 3.22e-3 35/41 (85.37%) MRE11;MUS81;RAD51B;...
Mismatch repair -2.49 0.00e+0 22/23 (95.65%) RFC3;POLD2;POLD1;...
Fanconi anemia pathway -2.50 0.00e+0 36/54 (66.67%) FANCE;BRIP1;FAN1;...
DNA replication -2.78 0.00e+0 34/36 (94.44%) RFC3;POLE3;POLD2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 20uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 1.11uM - 20uM 6H, 24H, 48H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H